Citations (10)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Matthew Javitt & Gary D. Novack. (2024) Advantages and disadvantages of using Rho kinase inhibitors to reduce intraocular pressure. Expert Review of Ophthalmology 19:3, pages 201-209.
Read now
Read now
Articles from other publishers (9)
Saima Shahid, Syed Wajahat A Rizvi, Adeeb A Khan, Humayoun Ashraf & Afeefa Akhter. (2024) Comparison of safety and efficacy of Netarsudil 0.02% and Bimatoprost 0.01% monotherapy and combination therapy in primary open-angle glaucoma and ocular hypertension. Indian Journal of Ophthalmology 72:3, pages 427-431.
Crossref
Crossref
Ingeborg Stalmans, Kin Sheng Lim, Francesco Oddone, Marek Fichtl, Jose I. Belda, Anton Hommer, Guna Laganovska, Cédric Schweitzer, Bogomil Voykov, Tomasz Zarnowski & Gábor Holló. (2023) MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension. Graefe's Archive for Clinical and Experimental Ophthalmology 262:1, pages 179-190.
Crossref
Crossref
Tyler Bahr, Scott Woolf, Hayley Favre & Corey Waldman. (2023) Comparison of netarsudil and latanoprostene bunod as adjuncts to maximum medical therapy in primary open-angle glaucoma. Canadian Journal of Ophthalmology 58:4, pages 356-360.
Crossref
Crossref
Manoj Chandra Mathur, P. Venkat Ratnam, S.J. Saikumar, Manuel John, Siddharth Ravishankar, M.B Dinesh, Priya Chandil, Kishore Pahuja, Vidya Cherlikar, Sunny Wadhwani, Pankaj Bendale, Ajit Hazari, Rajesh Mishra, Susheel Deshmukh, Rahul Raja Achlerkar, Devang Tilak Shah, Chanda Hingorani, Kaivan Shah, Pratik Topiwala, Sheetal Jani, Viral G. Rana, Nilay Kumar Majumdar, Debasis Chakrabarti, Rituparna Dey, Debabrata Halder, Sumit Choudhury, Ajeet Kumar, Sasmita Das, Ashok Kumar Nanda, Vidya Bhushan Kumar, Rama Dubey, Gulam Ali Kamdar, Alka Pandey, Sheetal Kishanpuria, Rajat Mohan Srivastava, Parul Singh, Sunil Kumar Verma, Neha Sharma & Rajeev Gupta. (2023) Netarsudil monotherapy as the initial treatment for open-angle glaucoma and ocular hypertension in Indian patients: A real-world evaluation of efficacy and safety. Indian Journal of Ophthalmology 71:6, pages 2500-2503.
Crossref
Crossref
Ning Xie, Cailan Xiao, Qiuai Shu, Bo Cheng, Ziwei Wang, Runxin Xue, Zhang Wen, Jinhai Wang, Haitao Shi, Daiming Fan, Na Liu & Feng Xu. (2023) Cell response to mechanical microenvironment cues via Rho signaling: From mechanobiology to mechanomedicine. Acta Biomaterialia 159, pages 1-20.
Crossref
Crossref
Alex T. Pham, Chris Bradley, Corinne Casey, Henry D. Jampel, Pradeep Y. Ramulu & Jithin Yohannan. (2023) Effectiveness of Netarsudil versus Brimonidine in Eyes already Being Treated with Glaucoma Medications at a Single Academic Tertiary Care Practice: A Comparative Study. Current Therapeutic Research 98, pages 100689.
Crossref
Crossref
Gavin Li, Esen Karamursel Akpek & Sumayya Ahmad. (2022) Glaucoma and Ocular Surface Disease: More than Meets the Eye. Clinical Ophthalmology Volume 16, pages 3641-3649.
Crossref
Crossref
Ramy Rashad, Catherine Zhu, Anna C. Kupcha, Alberto G. Distefano, Haben Kefella & Manishi A. Desai. (2022) Partial Stenosis and Complete Punctal Closure Following Topical Netarsudil Use for Glaucoma. Journal of Glaucoma 31:11, pages 920-925.
Crossref
Crossref
Reza Kianian, Samuel W. Hulbert, Simon K. Law & JoAnn Giaconi. (2022) Effectiveness of Topical ρ-Kinase Inhibitors in Veterans with Severe Glaucoma on Maximally Tolerated Medical Therapy. Optometry and Vision Science 99:8, pages 626-631.
Crossref
Crossref